

# Stratified medicine using the partykit package

**Heidi Seibold**, Achim Zeileis and Torsten Hothorn

Epidemiology, Biostatistics and Prevention Institute

University of Zurich



**University of  
Zurich** <sup>UZH</sup>

July, 2015



# What is stratified medicine?

Identifying subgroups of patients for whom the treatment has a different effect than for others.

Effect is:


- Stronger
- Lower
- Contrary

Subgroups are defined by patient characteristics.

# What is stratified medicine?

Goal: Find subgroups

$\hat{=}$  covariate  $\times$  treatment interactions



# MOB

## Model-based recursive partitioning (1)

Start with a parametric model

- ⇒ Find partitions based on patient characteristics.
- ⇒ Fit separate models in partitions.

```
mod(y ~ treatment, data = alldata)
```

```
mod(y ~ treatment, data = data1.1)
```

```
mod(y ~ treatment, data = data1.2)
```

mod can be e.g. `lm`, `glm`, `survreg`, ...

# Partitioning

How to find the Partitions?

Test independence between **score function** and **each patient characteristic**.

→ Detect instabilities in the intercept and treatment parameter.

- Partition if global p-value smaller than significance level
- Use as split variable the one corresponding to the smallest p-value

# Implementation

Example: glm

```
my.glm <- function(data, weights, family = binomial) {  
  
  mod <- glm(y ~ treatment, data = data,  
            subset = weights > 0, family = family)  
  
  # extract score function  
  ef <- sandwich::estfun(mod)  
  ret <- matrix(0, nrow = nrow(data), ncol = ncol(ef))  
  ret[weights > 0,] <- as.matrix(ef)  
  ret  
}  
  
tree <- ctree(y + treatment ~ z1 + z2 + z3,  
             data, ytrafo = my.glm)
```

# Data

## PRO-ACT database (2)

- Amyotrophic lateral sclerosis (ALS) patients
- Data of several clinical trials
- Treatment of interest:  
Riluzole, only approved drug against ALS (no cure)
- Primary endpoints of interest:  
ALS Functional Rating Scale (ALSFRS)

Question: Do all patients benefit the same from Riluzole?

# ALS Functional Rating Scale: ALSFRS





# Model


Gaussian model for the ALSFRS after six months taking into account the ALSFRS at the start of the treatment.

```
glm(ALSFRS6 ~ Riluzole + offset(log(ALSFRS0)),  
     family = gaussian(link = "log"))
```

	Value (CI)
$\alpha$	-0.16 (-0.17, -0.15)
$\beta_R$	0.01 ( 0.00, 0.03)

# ALSFRS example

## Results



## Summary/Outlook

- Interpretability
- Easy to use, flexible software
- More complex models possible, e.g.
  - More than two treatment options
  - Further covariate in the model
  - Multivariate outcomes
- Personalized instead of stratified medicine with cforest instead of ctree

# Literature



A. Zeileis, T. Hothorn, K. Hornik

*Model-Based Recursive Partitioning*

Journal of Computational and Graphical Statistics, 2008.



Massachusetts General Hospital, Neurological Clinical  
Research Institute

*Pooled Resource Open-Access ALS Clinical Trials Database*

<https://nctu.partners.org/ProACT/>, 2013.

Contact me: [heidi.seibold@uzh.ch](mailto:heidi.seibold@uzh.ch)